Humasis (CEO Cha Jeong-hak), a company specializing in on-site rapid testing, announced that it has obtained domestic permission for the COVID-19 molecular diagnostic kit developed this year while pursuing business diversification, such as entering the molecular diagnostic field, in preparation for the post-corona era.
According to the company, on the 27th, it obtained a manufacturing permit for its COVID-19 molecular diagnostic kit, ‘Humasis COVID-19 RT-PCR Kit’, from the Ministry of Food and Drug Safety and completed domestic permit registration. The Humasis COVID-19 RT-PCR Kit product is a product that can confirm whether or not you are infected with the Corona 19 virus, and can be tested through commercially available Bio-Rad’s CFX96 Real-time PCR and Thermo Fisher Scientific’s QuantStudio 5 Real-time PCR equipment. .
An official from Humasis said on the 29th, “Humasis COVID-19 RT-PCR Kit was judged suitable through an examination of technical documents for in vitro diagnostic medical devices from the Ministry of Food and Drug Safety, and through this domestic registration, it can be officially marketed in the domestic market.” “Humasis has been recognized for its technological prowess in molecular diagnosis beyond the existing field of antigen/antibody diagnosis, and has further solidified its position as a leading company in the field of in vitro diagnosis capable of both rapid and molecular diagnosis,” he said.
Meanwhile, Humasis is promoting business diversification such as blood sugar diagnosis, biochemical diagnosis, and remote diagnosis in addition to molecular diagnosis this year, and has recently focused on strengthening internal stability by purchasing additional office buildings to improve work efficiency.
